New drug MT-501 takes first step: safety check in healthy people
NCT ID NCT06762457
First seen Dec 29, 2025 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This early-phase trial tested the safety and tolerability of a new drug called MT-501 in 72 healthy adults aged 19 to 55. Participants received either single or multiple oral doses of MT-501 or a placebo. The main goal was to monitor for side effects and how the drug moves through the body, with no direct treatment benefit for volunteers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mirador Clinical Department
San Diego, California, 92121, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT-501
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.